Article Versions Notes

Venneker S, van Eenige R, Kruisselbrink AB, Palubeckaitė I, Taliento AE, Briaire-de Bruijn IH, Hogendoorn PCW, van de Sande MAJ, Gelderblom H, Mei H, et al. Histone Deacetylase Inhibitors as a Therapeutic Strategy to Eliminate Neoplastic “Stromal” Cells from Giant Cell Tumors of Bone. Cancers. 2022; 14(19):4708. https://doi.org/10.3390/cancers14194708

Venneker, Sanne, Robin van Eenige, Alwine B. Kruisselbrink, Ieva Palubeckaitė, Alice E. Taliento, Inge H. Briaire-de Bruijn, Pancras C. W. Hogendoorn, Michiel A. J. van de Sande, Hans Gelderblom, Hailiang Mei, and et al. 2022. "Histone Deacetylase Inhibitors as a Therapeutic Strategy to Eliminate Neoplastic “Stromal” Cells from Giant Cell Tumors of Bone" Cancers 14, no. 19: 4708. https://doi.org/10.3390/cancers14194708

Venneker, S., van Eenige, R., Kruisselbrink, A. B., Palubeckaitė, I., Taliento, A. E., Briaire-de Bruijn, I. H., Hogendoorn, P. C. W., van de Sande, M. A. J., Gelderblom, H., Mei, H., Bovée, J. V. M. G., & Szuhai, K. (2022). Histone Deacetylase Inhibitors as a Therapeutic Strategy to Eliminate Neoplastic “Stromal” Cells from Giant Cell Tumors of Bone. Cancers, 14(19), 4708. https://doi.org/10.3390/cancers14194708